Biocryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Mr. Thomas R. Staab, II as BioCryst’s new Chief Financial Officer, effective July 1, 2011, and that Mr. Stuart R. Grant, BioCryst’s current CFO, has agreed to extend his employment with the Company an additional month to June 30, 2011.

Back to news